O G Scharovsky
Overview
Explore the profile of O G Scharovsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
185
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Anselmino L, Baglioni M, Reynoso G, Rozados V, Scharovsky O, Rico M, et al.
Sci Rep
. 2023 May;
13(1):7923.
PMID: 37193722
Drug repositioning explores the reuse of non-cancer drugs to treat tumors. In this work, we evaluated the effect of the combination of chloroquine and propranolol on colorectal and triple-negative breast...
2.
Anselmino L, Baglioni M, Malizia F, Laluce N, Etichetti C, Marignac V, et al.
Sci Rep
. 2021 Apr;
11(1):8091.
PMID: 33854147
Drug repositioning refers to new uses for existing drugs outside the scope of the original medical indications. This approach fastens the process of drug development allowing finding effective drugs with...
3.
Rico M, Perroud H, Mainetti L, Rozados V, Scharovsky O
Cancer Invest
. 2014 Feb;
32(3):92-8.
PMID: 24499110
Metronomic chemotherapy refers to the chronic, equally spaced, delivery of low doses of chemotherapeutic drugs, without extended interruptions. Previously, we developed two combined metronomic schemes for the treatment of murine...
4.
Perroud H, Rico M, Alasino C, Pezzotto S, Rozados V, Scharovsky O
Indian J Cancer
. 2013 Aug;
50(2):115-21.
PMID: 23979202
Background: Metronomic chemotherapy (MCT) with cyclophosphamide (Cy) and celecoxib (Cel) has therapeutic efficacy and low toxicity profile in advanced breast cancer patients (ABCP), but no reliable biomarkers of response have...
5.
Mainetti L, Rico M, Fernandez-Zenobi M, Perroud H, Roggero E, Rozados V, et al.
Ann Oncol
. 2013 May;
24(9):2310-6.
PMID: 23666914
Background: Metronomic chemotherapy (MCT) refers to the chronic and equally spaced administration of low doses of different chemotherapy drugs, without extended rest periods. Herein, we investigated the therapeutic efficacy of...
6.
Rico M, Rozados V, Mainetti L, Zacarias Fluck M, Matar P, Scharovsky O
Exp Oncol
. 2012 Mar;
34(1):38-42.
PMID: 22453147
Aim: Experimental and clinical studies showed that the administration of cyclophosphamide (Cy) in low doses leads to an enhancement of the antitumor immune response. Our objective was to study the...
7.
Scharovsky O, Mainetti L, Rozados V
Curr Oncol
. 2009 Apr;
16(2):7-15.
PMID: 19370174
The introduction of the "maximum tolerated dose" in usual treatment protocols (and its concomitant overt toxicity) made necessary the imposition of rest periods between cycles of therapy-a practice that not...
8.
Rozados V, Hinrichsen L, McDonnell J, Scharovsky O
J Exp Clin Cancer Res
. 2005 Jun;
24(1):55-61.
PMID: 15943032
Our previous demonstration of an antimetastatic effect of lovastatin, both in rat sarcoma and lymphoma tumor-models, as well as the fact that lovastatin and radiation are able to stop the...
9.
Matar P, Rozados V, Gervasoni S, Scharovsky O
Int Immunopharmacol
. 2001 May;
1(2):307-19.
PMID: 11360931
In previous reports, we demonstrated an inhibitory effect of a single low-dose of cyclophosphamide (Cy) on spontaneous and experimental metastasis of a rat lymphoma (L-TACB). This antimetastatic effect could be...
10.
Scharovsky O, Rozados V, Gervasoni S, Matar P
J Biomed Sci
. 2000 Jul;
7(4):292-8.
PMID: 10895051
The most frequently detected oncogene alterations, both in animal and human cancers, are the mutations in the ras oncogene family. These oncogenes are mutated or overexpressed in many human tumors,...